Combination of Paclitaxel and R-flurbiprofen loaded PLGA nanoparticles suppresses glioblastoma growth on systemic administration

Simple item page
buir.contributor.authorKarlı-Oğuz, Kader
dc.citation.spage119076en_US
dc.citation.volumeNumber578en_US
dc.contributor.authorCaban-Toktas, S.
dc.contributor.authorŞahin, A.
dc.contributor.authorLule, S.
dc.contributor.authorEsendagli, G.
dc.contributor.authorVural, İ.
dc.contributor.authorKarlı-Oğuz, Kader K.
dc.contributor.authorSöylemezoğlu, F.
dc.contributor.authorMut, M.
dc.contributor.authorDalkara, T.
dc.contributor.authorKhan, M.
dc.contributor.authorCapan, Y.
dc.date.accessioned2021-02-24T10:37:02Z
dc.date.available2021-02-24T10:37:02Z
dc.date.issued2020
dc.departmentNational Magnetic Resonance Research Center (UMRAM)en_US
dc.description.abstractMalignant gliomas are highly lethal. Delivering chemotherapeutic drugs to the brain in sufficient concentration is the major limitation in their treatment due to the blood-brain barrier (BBB). Drug delivery systems may overcome this limitation and can improve the transportation through the BBB. Paclitaxel is an antimicrotubule agent with effective anticancer activity but limited BBB permeability. R-Flurbiprofen is a nonsteroidal antienflammatory drug and has potential anticancer activity. Accordingly, we designed an approach combining R-flurbiprofen and paclitaxel and positively-charged chitosan-modified poly-lactide-co-glycolic acid (PLGA) nanoparticles (NPs) and to transport them to glioma tissue. NPs were characterized and, cytotoxicity and cellular uptake studies were carried out in vitro. The in vivo efficacy of the combination and formulations were evaluated using a rat RG2 glioma tumor model. Polyethylene glycol (PEG) modified and chitosan-coated PLGA NPs demonstrated efficient cytotoxic activity and were internalized by the tumor cells in RG2 cell culture. In vivo studies showed that the chitosan-coated and PEGylated NPs loaded with paclitaxel and R-flurbiprofen exhibited significantly higher therapeutic activity against glioma. In conclusion, PLGA NPs can efficiently carry their payloads to glioma tissue and the combined use of anticancer and anti-inflammatory drugs may exert additional anti-tumor activity.en_US
dc.embargo.release2021-03-30
dc.identifier.doi10.1016/j.ijpharm.2020.119076en_US
dc.identifier.issn0378-5173
dc.identifier.urihttp://hdl.handle.net/11693/75550
dc.language.isoEnglishen_US
dc.publisherElsevieren_US
dc.relation.isversionofhttps://dx.doi.org/10.1016/j.ijpharm.2020.119076en_US
dc.source.titleInternational Journal of Pharmaceuticsen_US
dc.subjectGliomaen_US
dc.subjectPLGAen_US
dc.subjectNanoparticlesen_US
dc.subjectPaclitaxelen_US
dc.subjectR-flurbiprofenen_US
dc.subjectNanomedicineen_US
dc.titleCombination of Paclitaxel and R-flurbiprofen loaded PLGA nanoparticles suppresses glioblastoma growth on systemic administrationen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Combination_of_Paclitaxel_and_R-flurbiprofen_loaded_PLGA_nanoparticles_suppresses_glioblastoma_growth_on_systemic_administration.pdf
Size:
10.71 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

National Magnetic Resonance Research Center (UMRAM)